0001798749 false 0001798749 2021-08-06 2021-08-06 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 6, 2021

 

 

AEROVATE THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

 

Delaware   001-40544   83-1377888

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

 

Aerovate Therapeutics, Inc.

 

200 Berkeley Street, Floor 18, Boston, Massachusetts 02116 

(Address of principal executive offices, including zip code)

 

(617) 443-2400

(Registrant’s telephone number, including area code)

 

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trade
Symbol(s) 		Name of each exchange on which registered
Common Stock, $0.0001 par value per share AVTE The Nasdaq Global Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company  x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

 

 

 

 

Item 1.01 Entry into a Material Definitive Agreement

 

On August 6, 2021, Aerovate Therapeutics, Inc. (the “Company”) entered into a Lease (the “Lease”) with PDM 930 Unit, LLC (the “Landlord”) for a portion of the building located at 930 Winter Street, Waltham, Massachusetts 02451 (the “Premises”), which will serve as the Company’s corporate headquarters. Under the terms of the Lease, the Company will lease approximately 5,003 square feet at the Premises.

 

The base rent under the Lease is $43.00 per rentable square foot per year during the first year of the term, which is subject to scheduled annual increases of $1.00 per rentable square foot during the term. The Company’s obligation to pay rent under the Lease will start on the 121st day (the “Rent Commencement Date”) following the date on which the Landlord delivers the Premises to the Company with the certain improvements as set forth in the Lease, which is expected to occur on or about September 1, 2021. The term of the Lease is thirty-six months following the Rent Commencement Date, unless extended or earlier terminated pursuant to the terms of the Lease. The Company has the option to extend the lease for one additional period of three years.

 

The foregoing description of the Lease does not purport to be complete and is qualified in its entirety by reference to the Lease, a complete copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated by reference herein.

 

Item 2.03 Creation of a Direct Financial Obligation or an Obligation Under an Off-Balance Sheet Arrangement of a Registrant.

 

The information included in Item 1.01 of this Current Report on Form 8-K is incorporated into this Item 2.03 of this Current Report on Form 8-K by reference.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit
Number 		  Description
10.1   Lease, dated August 6, 2021, by and between the Registrant and PDM 930 Unit, LLC.
104   Cover Page Interactive Data File

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Aerovate Therapeutics, Inc.
     
Date: August 12, 2021 By: /s/ George A. Eldridge  
    George A. Eldridge
    Chief Financial Officer

 

 

Aerovate Therapeutics (NASDAQ:AVTE)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Aerovate Therapeutics Charts.
Aerovate Therapeutics (NASDAQ:AVTE)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Aerovate Therapeutics Charts.